Free Report: Revisting A 'Five Bagger'
We did a piece on immunotherapy play Fate Therapeutics (FATE) just over a year ago. It was one of the first free reports we published. That positive profile and recommendation came out when the shares traded right at $3.00 a share. As you can see from the chart below, it was one of the better calls of the last year. Today, we follow up with another piece on this biotech concern which despite its recent huge rally has seen some notable insider buying of late. Click here to download
Previous Update: An Update On Fate
Just over a year ago, we put out a positive analysis on a smart ‘Tier 4’ CAR-T concern that was trading south of $5.00 below in a free report. As can be seen from the chart below, it was a prescient call to this point. In this free report to end the month of April, we follow up on this small and evolving concern.
Initial Report: Buying Fate for A Cup of Coffee
In this free report we take a look at a small high risk/high reward biotech concern that has not only one of the more interesting ticker symbols in the market but also an intriguing and advancing pipeline. It also can currently be had for about the cost of a venti bold coffee at Starbucks.